


Eric Rabinowitz – J.P. Morgan Biography



Eric B. Rabinowitz

Managing Director

Co-Head Healthcare M&A

+1 (212) 622-6248

eric.rabinowitz@jpmorgan.com

Eric Rabinowitz rejoined JPMorgan in January 2019 as a Managing Director in the M&A group with a focus on the Healthcare industry. He previously worked for Bear Stearns as well as JPMorgan. Eric joined from Perrigo Company, where he served as Vice President of Corporate Development. Prior to Perrigo, Eric worked at Barclays Capital, where he was a Managing Director, Investment Banking, Healthcare Mergers & Acquisitions.

Eric has a Master of Business Administration from the University of Chicago, Booth School of Business, and a Bachelor of Science in Accounting from University of Florida.

Select transaction experience

- Clover Health \$3.7 billion merger with Social Capital Hedosophia Holdings Corp. III
 - Equality Health sale to General Atlantic
 - Talkspace \$1.4 billion merger with Hudson Executive
 - Centene \$1.8 billion acquisition of Magellan Health
 - Sharecare \$3.3 billion merger with Falcon Capital
 - Consonance-HFW \$200 million merger with Surrozen
 - Sale of Millennium Physician Group to CD&R
 - Corvidia \$2.1 billion sale to Novo Nordisk
 - AMN Healthcare \$475 million acquisition of Stratus Video
 - Centene \$17.3 billion acquisition of WellCare Health Plans
 - Sale of Waystar to EQT and CPPIB for \$2.7 billion
 - Sale of Perrigo API division to SK Capital for \$110 million
 - Sale of Perrigo's royalty interest in Tysabri to Royalty Pharma for up to \$2.85 billion
 - Perrigo defense of \$25.6 billion unsolicited offer from Mylan
 - Perrigo acquisition of a portfolio of leading over-the-counter brands from GlaxoSmithKline Consumer Healthcare for €200 million
 - Perrigo acquisition of Omega Pharma NV for €3.6 billion
 - Valeant \$46 billion failed hostile bid for Allergan
 - Perrigo \$8.6 billion acquisition of Elan
 - Acton Pharmaceuticals \$200 million sale to Meda
 - Cubist \$818 million acquisition of Trius Therapeutics
 - ProFibrix \$240 million sale to The Medicines Company
 - Metropolitan Health Networks \$850 million sale to Humana
 - Amerigroup \$4.9 billion sale to WellPoint
 - Dainippon Sumitomo Pharma \$430 million acquisition of Elevation Pharmaceuticals
 - Tenet Healthcare defense of \$7 billion unsolicited offer from Community Health Systems
 - Eli Lilly \$800 million acquisition of Avid Radiopharmaceuticals
 - Crucell €2.2 billion sale to Johnson & Johnson
 - Merck KGaA €4.9 billion sale of Generics Division to Mylan
 - New River Pharmaceuticals \$2.6 billion sale to Shire
 - Merck KGaA €14.6 billion failed hostile bid for Schering AG
 - The Blackstone Group \$1.75 billion acquisition of a majority equity interest in Vanguard Health Systems
-